Onartuzumab
- Product Name
- Onartuzumab
- CAS No.
- 1133766-06-9
- Chemical Name
- Onartuzumab
- Synonyms
- Onartuzumab;Onartuzumab (anti-MET);Research Grade Onartuzumab;RG-3638|||PRO-14396|||MetMAb;Research Grade Onartuzumab (DHC34202)
- CBNumber
- CB28080831
- Formula Weight
- 0
- MOL File
- Mol file
Onartuzumab Property
- form
- Liquid
- color
- Colorless to light yellow
Onartuzumab Chemical Properties,Usage,Production
Description
Onartuzumab is a monoclonal antibody that blocks the binding of HGF to the MET receptor.
Uses
Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity[1].
Clinical Use
Onartuzumab is ineffective in improving clinical outcomes in (i) combination with current first-line chemotherapy in advanced nonsquamous cell NSCLC , (ii) combination with erlotinib in previously treated stage IIIB or IV NSCLC patients (Phase III) , and (iii) combination with platinum-doublet chemotherapy in advanced squamous cell NSCLC (Phase II) .
in vivo
Onartuzumab (30 mg/kg, IP, twice a week for 2 mouth) suppresses tumor growth[3].
| Animal Model: | Human HGF-transgenic SCID mice implanted with BxPC3 tumor cells, nude (nu/nu) mice implanted with KP4 human pancreatic xenograft tumor cells[3] |
| Dosage: | 30 mg/kg |
| Administration: | IP, twice a week for 2 mouth |
| Result: | Suppressed tumor growth, but did not affect the mean in vivo human HGF levels. |
| Animal Model: | U-87 MG tumor-bearing mice[3] |
| Dosage: | 30 mg/kg |
| Administration: | IP, once |
| Result: | Resulted in profound TGI (tumor growth inhibition) with 4/10 mice demonstrating a partial response (>50% reduction in tumor size) and 6/10 mice demonstrating a complete response (100% tumor regression). |
References
[1] Merchant M, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):E2987-96. DOI:10.1073/pnas.1302725110
[2] Prell RA, et al. Placental and Fetal Effects of Onartuzumab, a Met/HGF Signaling Antagonist, When Administered to Pregnant Cynomolgus Monkeys. Toxicol Sci. 2018 Sep 1;165(1):186-197. DOI:10.1093/toxsci/kfy141
Onartuzumab Preparation Products And Raw materials
Raw materials
Preparation Products
Onartuzumab Suppliers
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 71826
- Advantage
- 60
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8000
- Advantage
- 62
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Country
- United States
- ProdList
- 32470
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ：422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 4008200310
- marketing@tsbiochem.com
- Country
- China
- ProdList
- 24964
- Advantage
- 58
- Tel
- 65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9868
- Advantage
- 58
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 6972
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11973
- Advantage
- 58
- Tel
- 021-59167510 18117107507
- vip@med-life.cn
- Country
- China
- ProdList
- 5002
- Advantage
- 58
- Tel
- 400-6206333 13167063860
- anhua.mao@aladdin-e.com
- Country
- China
- ProdList
- 48435
- Advantage
- 58